The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
The Future of Peptide‐based Drugs
Abstract
The suite of currently used drugs can be divided into two categories – traditional ‘small molecule’ drugs with typical molecular weights of <500 Da but with oral bioavailability, and much larger ‘biologics’ typically >5000 Da that are not orally bioavailable and need to be delivered via injection. Due to their small size, conventional small molecule drugs may suffer from reduced target selectivity that often ultimately manifests in human side‐effects, whereas protein therapeutics tend to be exquisitely specific for their targets due to many more interactions with them, but this comes at a cost of low bioavailability, poor membrane permeability, and metabolic instability. The time has now come to reinvestigate new drug leads that fit between these two molecular weight extremes, with the goal of combining advantages of small molecules (cost, conformational restriction, membrane permeability, metabolic stability, oral bioavailability) with those of proteins (natural components, target specificity, high potency). This article uses selected examples of peptides to highlight the importance of peptide drugs, some potential new opportunities for their exploitation, and some difficult challenges ahead in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349
Schafmeister, C. E., Po, J., & Verdine, G. L. (2000) · Journal of the American Chemical Society · doi:10.1021/ja000563a · Cited by 1,037
A revised set of potentials for β‐turn formation in proteins
Hutchinson, E. G., & Thornton, J. M. (1994) · Protein Science · doi:10.1002/pro.5560031206 · Cited by 937
Conus Venoms: A Rich Source of Novel Ion Channel-Targeted Peptides
TERLAU, H., & OLIVERA, B. M. (2004) · Physiological Reviews · doi:10.1152/physrev.00020.2003 · Cited by 897
Ziconotide: Neuronal Calcium Channel Blocker for Treating Severe Chronic Pain
Miljanich, G. P. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043363884 · Cited by 607
Research works printed but not linked: 16
- 10.1007/978-0-387-73657-0_201 · doi:10.1007/978-0-387-73657-0_201
- 10.1016/B978-0-12-396962-0.00013-6 · doi:10.1016/b978-0-12-396962-0.00013-6
- 10.1016/j.jconrel.2008.09.091 · doi:10.1016/j.jconrel.2008.09.091
- Fairlie D.P., 1995, Macrocyclic peptidomimetics: forcing peptides into bioactive conformations, Curr Med Chem, 2, 672, 10.2174/0929867302666220218001506 · doi:10.2174/0929867302666220218001506
- Fairlie D.P., 1998, Towards protein surface mimetics, Curr Med Chem, 5, 29, 10.2174/0929867305666220314194822 · doi:10.2174/0929867305666220314194822
- 10.1002/(SICI)1098-2299(199903/04)46:3/4<219::AID-DDR7>3.0.CO;2-S · DOI
- 10.1039/b307632f · doi:10.1039/b307632f
- 10.1021/jm030210x · doi:10.1021/jm030210x
- 10.1021/ja002416i · doi:10.1021/ja002416i
- 10.1016/0014-5793(90)81040-U · doi:10.1016/0014-5793(90)81040-u
- 10.2174/1381612033454900 · doi:10.2174/1381612033454900
- 10.1021/bc9003102 · doi:10.1021/bc9003102
- 10.1021/bc900361g · doi:10.1021/bc900361g
- Bowersox S., 1997, Pharmacokinetics of SNX‐111, a selective N‐type calcium channel blocker, in rats and cynomolgus monkeys, Drug Metab Dispos, 25, 379
- 10.2174/138161211798999401 · doi:10.2174/138161211798999401
- 10.1007/s00018-009-0159-3 · doi:10.1007/s00018-009-0159-3
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Coronavirus envelope protein: current knowledge
Schoeman, D., & Fielding, B. C. (2019) · Virology Journal · doi:10.1186/s12985-019-1182-0 · Cited by 2,074
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview
Bozorov, K., Zhao, J., & Aisa, H. A. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.07.005 · Cited by 854
Advances in targeting cyclic nucleotide phosphodiesterases
Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J., & Manganiello, V. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4228 · Cited by 776
Basics and Recent Advances in Peptide and Protein Drug Delivery
Bruno, B. J., Miller, G. D., & Lim, C. S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.104 · Cited by 754
Cyclic peptide therapeutics: past, present and future
Zorzi, A., Deyle, K., & Heinis, C. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.02.006 · Cited by 737
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669
Multifaceted Roles of Disulfide Bonds. Peptides as Therapeutics
Góngora-Benítez, M., Tulla-Puche, J., & Albericio, F. (2014) · Chemical Reviews · doi:10.1021/cr400031z · Cited by 655
Native Chemical Ligation and Extended Methods: Mechanisms, Catalysis, Scope, and Limitations
Agouridas, V., El Mahdi, O., Diemer, V., Cargoët, M., Monbaliu, J.-C. M., & Melnyk, O. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00712 · Cited by 650
Polyphenol‐Containing Nanoparticles: Synthesis, Properties, and Therapeutic Delivery
Guo, Y., Sun, Q., Wu, F., Dai, Y., & Chen, X. (2021) · Advanced Materials · doi:10.1002/adma.202007356 · Cited by 650
Unusual Amino Acids in Medicinal Chemistry
Blaskovich, M. A. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00319 · Cited by 635
HPEPDOCK: a web server for blind peptide–protein docking based on a hierarchical algorithm
Zhou, P., Jin, B., Li, H., & Huang, S.-Y. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky357 · Cited by 609
C–H Functionalization in the Synthesis of Amino Acids and Peptides
Noisier, A. F. M., & Brimble, M. A. (2014) · Chemical Reviews · doi:10.1021/cr500200x · Cited by 600
Residue-Specific Peptide Modification: A Chemist’s Guide
deGruyter, J. N., Malins, L. R., & Baran, P. S. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00536 · Cited by 573
Eloy, J. O., Claro de Souza, M., Petrilli, R., Barcellos, J. P. A., Lee, R. J., & Marchetti, J. M. (2014) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.09.029 · Cited by 529
Evaluation of the use of therapeutic peptides for cancer treatment
Marqus, S., Pirogova, E., & Piva, T. J. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0328-x · Cited by 512
Macrocycles: lessons from the distant past, recent developments, and future directions
Yudin, A. K. (2015) · Chemical Science · doi:10.1039/c4sc03089c · Cited by 493
THPdb: Database of FDA-approved peptide and protein therapeutics
Usmani, S. S., Bedi, G., Samuel, J. S., Singh, S., Kalra, S., Kumar, P., Ahuja, A. A., Sharma, M., Gautam, A., & Raghava, G. P. S. (2017) · PLOS ONE · doi:10.1371/journal.pone.0181748 · Cited by 485
The emergence of peptides in the pharmaceutical business: From exploration to exploitation
Uhlig, T., Kyprianou, T., Martinelli, F. G., Oppici, C. A., Heiligers, D., Hills, D., Calvo, X. R., & Verhaert, P. (2014) · EuPA Open Proteomics · doi:10.1016/j.euprot.2014.05.003 · Cited by 456
Orally Absorbed Cyclic Peptides
Nielsen, D. S., Shepherd, N. E., Xu, W., Lucke, A. J., Stoermer, M. J., & Fairlie, D. P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00838 · Cited by 445
Self-citationAccurate de novo design of hyperstable constrained peptides
Bhardwaj, G., Mulligan, V. K., Bahl, C. D., Gilmore, J. M., Harvey, P. J., Cheneval, O., Buchko, G. W., Pulavarti, S. V. S. R. K., Kaas, Q., Eletsky, A., et al. (2016) · Nature · doi:10.1038/nature19791 · Cited by 440
Self-citationPeptide Design Principles for Antimicrobial Applications
Torres, M. D. T., Sothiselvam, S., Lu, T. K., & de la Fuente-Nunez, C. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.12.015 · Cited by 438
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers
Haddadzadegan, S., Dorkoosh, F., & Bernkop-Schnürch, A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114097 · Cited by 424
Constraining Cyclic Peptides To Mimic Protein Structure Motifs
Hill, T. A., Shepherd, N. E., Diness, F., & Fairlie, D. P. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201401058 · Cited by 418
Self-citationPeptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs)
Cooper, B. M., Iegre, J., O' Donovan, D. H., Ölwegård Halvarsson, M., & Spring, D. R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00556h · Cited by 414
Targeted Protein Degradation: from Chemical Biology to Drug Discovery
Cromm, P. M., & Crews, C. M. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.05.024 · Cited by 412
CancerPPD: a database of anticancer peptides and proteins
Tyagi, A., Tuknait, A., Anand, P., Gupta, S., Sharma, M., Mathur, D., Joshi, A., Singh, S., Gautam, A., & Raghava, G. P. S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku892 · Cited by 397
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P., & Mason, J. M. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01291-6 · Cited by 397
Self-citationNew Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382
Thapa, R. K., Diep, D. B., & Tønnesen, H. H. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.12.025 · Cited by 378
In silico ADME/T modelling for rational drug design
Wang, Y., Xing, J., Xu, Y., Zhou, N., Peng, J., Xiong, Z., Liu, X., Luo, X., Luo, C., Chen, K., et al. (2015) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583515000190 · Cited by 367
Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications
Martins, C., Sousa, F., Araújo, F., & Sarmento, B. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701035 · Cited by 362
Progress in biopharmaceutical development
Kesik‐Brodacka, M. (2018) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1617 · Cited by 353
Peptide therapeutics: Targeting the undruggable space
Tsomaia, N. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.014 · Cited by 348
Muheem, A., Shakeel, F., Jahangir, M. A., Anwar, M., Mallick, N., Jain, G. K., Warsi, M. H., & Ahmad, F. J. (2016) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2014.06.004 · Cited by 343
Clinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Mechanism Matters: A Taxonomy of Cell Penetrating Peptides
Kauffman, W. B., Fuselier, T., He, J., & Wimley, W. C. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.10.004 · Cited by 333
Stimuli‐responsive nanotherapeutics for precision drug delivery and cancer therapy
Qiao, Y., Wan, J., Zhou, L., Ma, W., Yang, Y., Luo, W., Yu, Z., & Wang, H. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1527 · Cited by 332
Cicero, A. F. G., Fogacci, F., & Colletti, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13608 · Cited by 317
ToxinPred 3.0: An improved method for predicting the toxicity of peptides
Rathore, A. S., Choudhury, S., Arora, A., Tijare, P., & Raghava, G. P. S. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108926 · Cited by 317
Machine intelligence in peptide therapeutics: A next‐generation tool for rapid disease screening
Basith, S., Manavalan, B., Hwan Shin, T., & Lee, G. (2020) · Medicinal Research Reviews · doi:10.1002/med.21658 · Cited by 312
Peptide-based cancer therapy: Opportunity and challenge
Wu, D., Gao, Y., Qi, Y., Chen, L., Ma, Y., & Li, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.002 · Cited by 306
Mendive-Tapia, L., Preciado, S., García, J., Ramón, R., Kielland, N., Albericio, F., & Lavilla, R. (2015) · Nature Communications · doi:10.1038/ncomms8160 · Cited by 297
Hydrocarbon Stapled Peptides as Modulators of Biological Function
Cromm, P. M., Spiegel, J., & Grossmann, T. N. (2015) · ACS Chemical Biology · doi:10.1021/cb501020r · Cited by 290
Site-Selective C(sp3)–H Functionalization of Di-, Tri-, and Tetrapeptides at the N-Terminus
Gong, W., Zhang, G., Liu, T., Giri, R., & Yu, J.-Q. (2014) · Journal of the American Chemical Society · doi:10.1021/ja510233h · Cited by 288
Mechanistic Landscape of Membrane-Permeabilizing Peptides
Guha, S., Ghimire, J., Wu, E., & Wimley, W. C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00520 · Cited by 280
Peptidomimetic therapeutics: scientific approaches and opportunities
Qvit, N., Rubin, S. J. S., Urban, T. J., Mochly-Rosen, D., & Gross, E. R. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.003 · Cited by 273
A Web Server and Mobile App for Computing Hemolytic Potency of Peptides
Chaudhary, K., Kumar, R., Singh, S., Tuknait, A., Gautam, A., Mathur, D., Anand, P., Varshney, G. C., & Raghava, G. P. S. (2016) · Scientific Reports · doi:10.1038/srep22843 · Cited by 267
Santos, K. B., Guedes, I. A., Karl, A. L. M., & Dardenne, L. E. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00905 · Cited by 265
Direct decarboxylative Giese reactions
Kitcatt, D. M., Nicolle, S., & Lee, A.-L. (2022) · Chemical Society Reviews · doi:10.1039/d1cs01168e · Cited by 257
TGF-β signaling in cancer metastasis
Xie, F., Ling, L., Van Dam, H., Zhou, F., & Zhang, L. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx123 · Cited by 231
The greening of peptide synthesis
Lawrenson, S. B., Arav, R., & North, M. (2017) · Green Chemistry · doi:10.1039/c7gc00247e · Cited by 205
Systematic Targeting of Protein–Protein Interactions
Modell, A. E., Blosser, S. L., & Arora, P. S. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.008 · Cited by 184
Potent peptidic fusion inhibitors of influenza virus
Kadam, R. U., Juraszek, J., Brandenburg, B., Buyck, C., Schepens, W. B. G., Kesteleyn, B., Stoops, B., Vreeken, R. J., Vermond, J., Goutier, W., et al. (2017) · Science · doi:10.1126/science.aan0516 · Cited by 165
Bockus, A. T., Schwochert, J. A., Pye, C. R., Townsend, C. E., Sok, V., Bednarek, M. A., & Lokey, R. S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00919 · Cited by 135
Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy
Yin, H., Zhou, X., Huang, Y.-H., King, G. J., Collins, B. M., Gao, Y., Craik, D. J., & Wang, C. K. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08132 · Cited by 57
Self-citationRevolutionizing peptide‐based drug discovery: Advances in the post‐AlphaFold era
Chang, L., Mondal, A., Singh, B., Martínez‐Noa, Y., & Perez, A. (2024) · WIREs Computational Molecular Science · doi:10.1002/wcms.1693 · Cited by 56
Masui, H., & Fuse, S. (2022) · Organic Process Research & Development · doi:10.1021/acs.oprd.2c00074 · Cited by 38
Protein–Protein Interaction Modulators for Epigenetic Therapies
(2018) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/bs.apcsb.2017.06.002 · Cited by 31
Food Peptides for the Nutricosmetic Industry
Dini, I., & Mancusi, A. (2023) · Antioxidants · doi:10.3390/antiox12040788 · Cited by 28
Recent advances in automated protein design and its future challenges
Setiawan, D., Brender, J., & Zhang, Y. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1465922 · Cited by 26
Sabatino, G., D’Ercole, A., Pacini, L., Zini, M., Ribecai, A., Paio, A., Rovero, P., & Papini, A. M. (2021) · Organic Process Research & Development · doi:10.1021/acs.oprd.0c00490 · Cited by 21
Dar, G. H., Gopal, V., & Rao, M. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.01.017 · Cited by 16
Maharaja Agrasen Himalayan Garhwal University, P., Kumar, P., Goel, A., Maharaja Agrasen Himalayan Garhwal University, P., Dash, B., Amity Institute of Pharmacy, A. U., Rishishwar, P., Maharaja Agrasen Himalayan Garhwal University, P., S, J., Alpha Pharma Industries, K. 2., et al. (2025) · Chinese Journal of Applied Physiology · doi:10.62958/j.cjap.2025.001 · Cited by 6
Newkirk, S. E., Kelly, J. J., Hourn, N., Bhandari, S., Spencer, N., & Pires, M. M. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00291 · Cited by 2
Metadata
- Authors
- Craik, D. J., Fairlie, D. P., Liras, S., & Price, D.
- Venue
- Chemical Biology & Drug Design
- Publisher
- Wiley
- Published
- 2012-12-17
- Volume
- 81
- Issue
- 1
- Pages
- 136-147
- ISSN
- 1747-0277 (ISSN-L)
- 1747-0285
- OpenAlex
- W1860382351
- Cited by
- 1,979
- References
- 64
- FWCI
- 32.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.